AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

In their own responses to the senators’ inquiries last fall, both Pfizer and Lilly emphasized the independence of their ...

"Billionaire" and "successful hedge fund manager" are titles that carry significant weight on Wall Street. These and others ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

Novo Nordisk faces formidable challenges from Eli Lilly and new rivals, but its first-mover advantage and expanded ...

As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...

Companies in the US, including Novo Nordisk, Boeing and Shein, are forming task forces to address the impact of Donald ...

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But ...

But as the drugstore chain (WBA) prepares to go private and its rival CVS Health Inc. (CVS) experiments with smaller stores, some analysts and researchers see a possible future with even fewer ...

Eli Lilly has raised its revenue guidance for 2024 ... fuelled by the end of supply constraints for starting doses. The company reported a stellar 36% increase in second-quarter sales to $11.3 ...